Trials / Completed
CompletedNCT00292864
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Sunesis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.
Detailed description
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body), preliminary evaluation of biomarkers to see how the levels of certain proteins change after administration of SNS-032; assessment of the effects of SNS-032 on QT interval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNS-032 Injection |
Timeline
- Start date
- 2006-01-01
- Completion
- 2007-12-01
- First posted
- 2006-02-16
- Last updated
- 2012-06-07
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00292864. Inclusion in this directory is not an endorsement.